Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics

PI 3-Kinase Signaling Pathways in Disease (B8)

Organizer(s): Peter M. Finan and Lewis C. Cantley
February 15 - 20, 2007
Hilton Santa Fe/Historic Plaza · Santa Fe, New Mexico
Abstract Deadline: October 16, 2006
Late Abstract Deadline: November 15, 2006
Scholarship Deadline: October 16, 2006
Early Registration Deadline: December 15, 2006

Supported by Merck Research Laboratories

This meeting took place in the 2007 season.

For a complete list of the meetings for the upcoming/current season,
see our meeting list, or search for a meeting.

Summary of Meeting
The PI 3-kinase signaling pathway is emerging as a promising therapeutic target in a number of human diseases including cancer, inflammation and heart disease. Mutations in the PIK3CA gene and the deletion of lipid phosphatase, PTEN, are widespread in many tumors. Mouse models which target individual PI 3-kinase isoforms have shed light on the roles of these enzymes in immune cell function, mast cell degranulation and leukocyte migration. One of the most exciting developments in this field is the discovery of new PI 3-kinase inhibitors. However, identifying the indications that will provide the best opportunity to develop these inhibitors is the subject of intense debate. This meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI 3-kinase pathway in disease, drawing on human pathophysiology and genetics, mouse models and preclinical data with new PI 3-kinase inhibitors.

Thursday, February 15
3:00 - 7:30 PM	Registration	Promenade
6:30 - 7:30 PM	Refreshments	Promenade
7:30 - 8:30 PM	Keynote Address: Targeting the PI3K Pathway	Mesa A-B
	Lewis C. Cantley, Harvard Medical School Control of Cell Growth by LKB1/AMPK versus PI3K/AKT: Implications for Cancer and Diabetes
Friday, February 16
7:00 - 8:00 AM	Breakfast	Chamisa
8:00 - 11:00 AM	PI 3-Kinase Signaling I	Mesa A-B
	* Peter M. Finan, Novartis Institutes for BioMedical Research, Inc.
	Len R. Stephens, Babraham Institute Signaling via PI3Ks
	Jan Domin, Imperial College London Activation and Function of Class II Phosphoinositide 3-Kinase Enzymes
	Emilio Hirsch, University of Torino What Function for PI3Kbeta?
	Marco Falasca, Barts & The London School of Medicine & Dentistry Short Talk: Emerging Roles of Phosphatidylinositol-3-Phosphate as a Dynamic Intracellular Second Messenger
	Takehiko Sasaki, Akita University School of Medicine Short Talk: Control of Chemotaxis by PI3Ks and PtdIns(3,4,5)P3 Phosphatases
9:20 - 9:40 AM	Coffee Break	Promenade
11:00 AM - 1:00 PM	Poster Setup	Ortiz
1:00 - 10:00 PM	Poster Viewing	Ortiz
4:30 - 5:00 PM	Coffee Available	Promenade
5:00 - 7:00 PM	PI 3-Kinase Signaling II	Mesa A-B
	* Len R. Stephens, Babraham Institute
	Dario Alessi, University of Dundee PDK1 Signaling
	Brendan D. Manning, Harvard School of Public Health Signal Integration and Feedback Inhibition Within the TSC-mTORC1 Signaling Network

	Bruno D. Fonseca, University of British Columbia, Life Sciences Institute Short Talk: PRAS40, a Novel Raptor Binding Partner, is Essential for the Function of the mTORC1 Complex
	Andreas Androutsellis-Theotokis, NINDS, National Institutes of Health Short Talk: STAT3-Ser727: A Stem Cell Target for Cancer and Regeneration, Downstream of PI3 Kinase
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Ortiz/Chamisa
7:30 - 10:00 PM	Poster Session 1	Ortiz/Chamisa
Saturday, February 17
7:00 - 8:00 AM	Breakfast	Chamisa
8:00 - 11:00 AM	Dissecting PI 3-Kinase Isoform Specificity	Mesa A-B
	* Matthias P. Wymann, University of Basel
	Bart Vanhaesebroeck, Barts & The London School of Medicine Dissecting PI 3-kinase Function Using Genetically Modified Mice
	Kevan M. Shokat, University of California, San Francisco PI3K Target Validation Using a Matrix of Selective Small Molecule PI3K Inhibitors


	John Doukas, Vical Incorporated PI3K gamma/delta Inhibitors as Therapeutics for Inflammatory-Based Diseases
	Christian Rommel, Intellikine, Inc. PI 3-kinase gamma Inhibitors
	Peter Lamb, Exelixis Short Talk: Characterization of Selective Inhibitors of Class I and Class III PI3 Kinases
9:20 - 9:40 AM	Coffee Break	Promenade
11:00 AM - 1:00 PM	Poster Setup	Ortiz
1:00 - 10:00 PM	Poster Viewing	Ortiz
4:30 - 5:00 PM	Coffee Available	Promenade
5:00 - 7:00 PM	PI 3-Kinase Signaling in the Immune System	Mesa A-B
	* Bart Vanhaesebroeck, Barts & The London School of Medicine
	Matthias P. Wymann, University of Basel PI3K - Context-dependent Signaling
	David A. Fruman, University of California, Irvine Role of Class IA PI3K in T Cell Function and Autoimmunity

	Klaus Okkenhaug, Babraham Institute The PI3K p110delta Regulates T Cell Differentiation and Regulation
	Subha Krishnan, Indiana University School of Medicine Short Talk: Differential Role of p85á and p85â Regulatory Subunits of Class IA PI-3Kinase in Mast Cell Growth and Differentiation
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Ortiz/Chamisa
7:30 - 10:00 PM	Poster Session 2	Ortiz/Chamisa
Sunday, February 18
7:00 - 8:00 AM	Breakfast	Chamisa
8:00 - 11:00 AM	Crosstalk to Other Pathways	Mesa A-B
	* George Thomas, University of Cincinnati
	Brian A. Hemmings, Friedrich Miescher Institute Effectors Downstream of PI 3-Kinase: AKT/PKB
	Yan Luo, Abbott Laboratories Potent and Selective Inhibitors of Akt Delay Tumor Growth and Sensitize Tumors to Chemotherapy in vivo
	Heidi A. Lane, Basilea Pharmaceutica Ltd. The mTOR Inhibitor RAD001 (Everolimus): A Promising Therapeutic for the Treatment of Human Cancers
	Igor Vivanco, University of California, Los Angeles Short Talk: Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN
9:20 - 9:40 AM	Coffee Break	Promenade
11:00 AM - 1:00 PM	Poster Setup	Ortiz
1:00 - 10:00 PM	Poster Viewing	Ortiz
4:30 - 5:00 PM	Coffee Available	Promenade
5:00 - 7:00 PM	PI 3-Kinase Signaling and Control of Metabolism	Mesa A-B
	* Lewis C. Cantley, Harvard Medical School
	George Thomas, University of Cincinnati The Role of the Nutrient Input in TSC1/2-Rheb Mediated mTOR signaling
	Morris J. Birnbaum, University of Pennsylvania Regulation of Glucose and Lipid Metabolism by Akt/PKB
	Takashi Kadowaki, University of Tokyo Insulin Signaling

	Cheryl L. Walker, University of Texas MD Anderson Cancer Center Short Talk: Activation of AMPK Signaling in TSC2-Deficient Cells Regulates p27 Localization and Function
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Ortiz/Chamisa
7:30 - 10:00 PM	Poster Session 3	Ortiz/Chamisa
Monday, February 19
7:00 - 8:00 AM	Breakfast	Chamisa
8:00 - 11:00 AM	PI 3-Kinase Signaling and Cancer I	Mesa A-B
	* Paul Workman, Institute of Cancer Research
	Thomas M. Roberts, Dana Farber Cancer Institute Targeting PI3 Kinase Isoforms in Cancer
	Paul S. Mischel, University of California, Los Angeles mTOR Inhibitors in Glioblastoma

	Pier Paolo Pandolfi, BIDMC/Harvard Medical School PTEN and Tumorigensis

	Levi A. Garraway, Dana Farber Cancer Institute Somatic Alterations of PTEN and PIK3CA Elicit Distinct Cancer Phenotypes
	Surbhi Gupta, Short Talk: The Interaction of Ras with p110alpha is Required for Ras-Driven Tumorigenesis and for Normal Lymphatic Development
9:20 - 9:40 AM	Coffee Break	Promenade
4:30 - 5:00 PM	Coffee Available	Promenade
5:00 - 7:00 PM	PI 3-Kinase Signaling and Cancer II	Mesa A-B
	* Peter M. Finan, Novartis Institutes for BioMedical Research, Inc.
	Jonathan M. Backer, Albert Einstein College Of Medicine Mechanism of Oncogenic Deregulation of Class IA PI 3-Kinases
	Paul Workman, Institute of Cancer Research Drugging the PI3 Kinome for Cancer Treatment
	Carlos García-Echeverría, Novartis Pharma AG Blocking the PI3K/PKB Signaling Pathway in Tumor Cells: A Challenging and Ardous Drug Discovery Enterprise
	Lewis C. Cantley, Harvard Medical School Closing Statement
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Mesa C
8:00 - 11:00 PM	Entertainment	Mesa C
Tuesday, February 20
	Departure

*Session Chair †Speaker invited, not yet responded.